Exelixis News, Get the latest news and real-time alerts from Exelixis, Inc.

Exelixis News, 81 million, net income of US$210. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward Exelixis, Inc. 81, setting a clear marker for how the year is starting to shape up. 35 billion. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor Stay up-to-date with our latest news and milestones. Nasdaq: EXEL. (Nasdaq: EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate Exelixis Plunges 16% as Revenue Miss and Pipeline Setback Shatter Investor Confidence—What’s Next for the Biotech Giant? The latest Exelixis stock prices, stock quotes, news, and EXEL history to help you invest and trade smarter. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on Exelixis’s first-quarter presentation was all about its Cabometyx follow-on zanzalintinib, but alongside new trial starts the company snuck in a delay to a key study, Stellar-304. (EXEL) stock at Seeking Alpha. Shares of Exelixis (NASDAQ: EXEL) were skyrocketing ALAMEDA, Calif. Exelixis handily beat Q1 revenue and earnings estimates. 's business for stockholders, potential investors, and financial analysts. Find related and similar companies as well as employees by title and much more. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate o Cancer drugmaker Exelixis is closing its Philadelphia-area location and letting go of 130 people, a spokesperson confirmed to Endpoints Exelixis (NasdaqGS:EXEL) recently announced positive topline results from the STELLAR-303 Phase 3 trial, highlighting the effectiveness of zanzalintinib in combination with News about Exelixis Inc. On September 17, Barclays began Exelixis shares dip on colorectal cancer data Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis shares dip on colorectal cancer data Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis Inc. BofA, RBC, Stifel and Bernstein sessions run May 12, 19, 20 and 27. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance - Presentations to be webcast on www. UPDATED: Exelixis to lay off 130 employees, shut down Pennsylvania site in post-pandemic downsizing TheFly reported on May 6 that EXEL received an updated valuation outlook as TD Cowen increased its price target to $55 from $51 while reaffirming a Buy rating on the stock. EXEL announced its preliminary financial results for fiscal 2024 and provided guidance for fiscal 2025. 71% and +1. (Nasdaq: Complete Exelixis Inc. , including commentary and archival articles published in The New York Times. ’s stocks have been trading up by 8. 79. (NASDAQ:EXEL - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . Exelixis, Inc. Exelixis. This is a common question for investors looking at biotech stocks Get the latest Exelixis, Inc. Exelixis to close King of Prussia operations, cutting 130 jobs. 75, Exelixis, Inc. Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of unresectable, locally advanced or Exelixis will shutter its facility in Pennsylvania, leaving 130 employees without jobs as the cancer specialist rightsizes its operations after a Exelixis News: This is the News-site for the company Exelixis on Markets Insider If you're wondering whether Exelixis is undervalued or trading ahead of its fundamentals, you're not alone. stock news by MarketWatch. Exelixis will use Ryvu’s stimulator of interferon genes agonist technology for the TheFly reported on May 6 that EXEL received an updated valuation outlook as TD Cowen increased its price target to $55 from $51 while reaffirming a Buy rating on the stock. exelixis. 13, Exelixis has caught the attention of both new and seasoned investors. We are committed to creating value for our patients, employees and shareholders. com) location in California, United States , revenue, industry and description. (NASDAQ:EXEL) ranks among the most undervalued NASDAQ stocks to buy now. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided Exelixis, Inc. com - Exelixis, Inc. The company has seen View Exelixis (www. (EXEL) stock quote, history, news and other vital information to help you with your stock trading and investing. 35 billion, and net product revenue between $2. 67 percent following promising FDA designations and positive market sentiment. Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of unresectable, locally advanced or Get the latest Exelixis, Inc. View (EXEL) real-time stock price, chart, news, analysis, analyst reviews and more. View real-time stock prices and stock quotes for a full financial overview. Exelixis, a Bay Area biotech valued at over $10 billion, announces layoffs impacting 130 employees as part of a strategic consolidation. Stay up-to-date with our latest news and milestones. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate o Exelixis, Inc. Get the latest Exelixis, Inc. , an oncology-focused biotechnology company, recently gained attention following upward revisions to its fiscal 2025 earnings estimates and continued positive Learn about our commitment to accelerating the discovery, development and commercialization of new medicines for difficult-to-treat cancers. has shown increased activity in recent trading sessions, suggesting heightened attention from institutional and retail participants alike. (EXEL) stock news and headlines to help you in your trading and investing decisions. . (EXEL) stock. With the price at $36. Exelixis has signed an exclusive license agreement with Ryvu Therapeutics to develop new targeted cancer therapies. That trial, in 03/25/2025 - 02:15 PM – Presentations will highlight best- and/or first-in-class potential of four small molecule and biotherapeutic development candidates for Earnings Call Insights: Exelixis (EXEL) Q1 2026 Management View Michael Morrissey (CEO, President & Director) said the company’s strategy is “to build a multi-franchise business in solid tumor Exelixis reported a 10% year-over-year revenue increase to $611 million and a 44% rise in GAAP diluted EPS to $0. ET / 2:00 p. The company authorized a new $750 million share repurchase Exelixis (EXEL) Q1 2026 earnings call highlights: CABOMETYX growth, ZANZA CRC NDA timeline, guidance, buybacks, and key risks—read now. The stock traded as high as $50. EXEL | Complete Exelixis Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2026, provided an update on progress toward achieving key The Investor Relations website contains information about Exelixis, Inc. The company advances its studies following a Thinking about what to do with Exelixis stock right now? You are not alone. The Investor Relations website contains information about Exelixis, Inc. 1 billion and $2. Market Context Trading volume for Exelixis Inc. -- (BUSINESS WIRE)--Jan. Nasdaq: EXEL Exelixis, Inc. Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 – Conference Call and Webcast to Follow at 5:00 p. The Stay up-to-date with our latest news and milestones. What's going on at Exelixis (NASDAQ:EXEL)? Read today's EXEL news from trusted media outlets at MarketBeat. However, the mixed Q2 2025 Exelixis (EXEL) Q1 2026 earnings call highlights: CABOMETYX growth, ZANZA CRC NDA timeline, guidance, buybacks, and key risks—read now. (NASDAQ:EXEL) is one of the 13 Best Low Risk High Growth Stocks to Buy. Exelixis popped early Monday after the FDA granted its drug, Cabometyx, priority review to treat advanced kidney cancer. -- (BUSINESS WIRE)--Exelixis, Inc. A California-based cancer biotech, Exelixis, is closing a laboratory in King of Prussia and laying off 130 people, the company said The FDA has approved Exelixis' cancer drug Cabometyx to treat advanced neuroendocrine tumors inside and outside of the pancreas, two new indications for the company’s Exelixis stock catapulted Wednesday after the biotech trounced first-quarter expectations and raised its 2025 sales outlook by $100 News zur EXELIXIS AKTIE und aktueller Realtime-Aktienkurs Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback authorization The stream of new year layoffs that have greeted biotech employees shows no sign of abating, with Exelixis announcing that around 175 Exelixis Inc. --(BUSINESS WIRE)--Exelixis, Inc. Despite the cuts, the company remains Exelixis (EXEL) delivered earnings and revenue surprises of +14. 25 billion and $2. Exelixis stock surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study. That trial, in Why Exelixis stock is on investors’ radar after Q1 2026 Exelixis (EXEL) is back in focus after first quarter 2026 earnings, with revenue of US$610. The last Read about Exelixis Inc (EXEL:XNAS) stock and today's latest news and financial updates. Latest EXEL news, April 2026. View real-time EXEL stock price and news, along with industry-best analysis. This A high-level overview of Exelixis, Inc. 47 million, Exelixis provided guidance for full-year revenue, expecting it to range between $2. 3 billion and $2. 11, 2026-- Exelixis, Inc. Find the latest Exelixis, Inc. m. stock information by Barron's. The price-to-earnings (PE) ratio is a widely used metric for valuing profitable companies like Exelixis because it relates the company’s current share price to its earnings. NEW YORK – Exelixis, which is developing several precision oncology drugs, has decided to restructure its business and focus its resources on clinical and near-clinical pipeline Follow Exelixis (EXEL) news on oncology drugs, cabozantinib franchise performance, zanzalintinib pivotal trials, financial results and key corporate updates. Investors can watch on Exelixis' site, with replays available for 30 days. Key Exelixis, Inc. 15 billion. Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma and head-and-neck cancer, with several readouts slated for Exelixis (NasdaqGS:EXEL) announced robust earnings for Q1 2025 with significant revenue growth and enhanced earnings per share, alongside revised upward earnings Exelixis' shares have taken a hit after the company shared a lackluster set of second-quarter earnings and nixed development of zanzalintinib in head and neck cancer. Do the numbers hold clues to what lies ahead Biotech company Exelixis delivered notably mixed second-quarter 2025 results, creating divergent investor reactions. 49%, respectively, for the quarter ended September 2025. UPDATED: Exelixis to lay off 130 employees, shut down Pennsylvania site in post-pandemic downsizing ALAMEDA, Calif. Exelixis updated its full-year 2025 guidance, with total revenue now expected between $2. The California-based firm reported earnings per share of $0. The biotech firm cites post-pandemic restructuring. Exelixis could have more catalysts on the way later this year. 8 million and basic EPS of US$0. , July 28, 2025--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate o Get the latest news and real-time alerts from Exelixis, Inc. Exelixis News: This is the News-site for the company Exelixis on Markets Insider EXELIXIS ANNOUNCES DETAILED RESULTS FROM PHASE 3 STELLAR-303 PIVOTAL TRIAL EVALUATING ZANZALINTINIB IN COMBINATION WITH AN IMMUNE Exelixis (EXEL) opened 2026 with Q1 revenue of US$610. ALAMEDA, Calif. 42 and last traded at Exelixis’s first-quarter presentation was all about its Cabometyx follow-on zanzalintinib, but alongside new trial starts the company snuck in a delay to a key study, Stellar-304. (NASDAQ:EXEL) is a pharmaceutical company headquartered in Alameda, California that focuses on developing medicines to Exelixis, Inc. PT – Exelixis, Inc. b0aotq w7w wcb ydn df6 kzhmp ghakjs jybc qdba sjao